Search results
Results from the WOW.Com Content Network
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase , a viral DNA polymerase that is required for replication of HIV and other retroviruses .
The reverse transcriptase of HIV-1 has been the main foundation for the development of anti-HIV drugs. [5] The first nucleoside reverse-transcriptase inhibitor with in vitro anti-HIV activity was zidovudine. [6] Since zidovudine was approved in 1987, six nucleosides and one nucleotide reverse-transcriptase inhibitor (NRTI) have been approved by ...
ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. [6] It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. [6] Zidovudine was first described in 1964. [7] It was resynthesized from a public-domain formula by Burroughs Wellcome. [8]
A reverse transcriptase (RT) is an enzyme used to convert RNA genome to DNA, a process termed reverse transcription.Reverse transcriptases are used by viruses such as HIV and hepatitis B to replicate their genomes, by retrotransposon mobile genetic elements to proliferate within the host genome, and by eukaryotic cells to extend the telomeres at the ends of their linear chromosomes.
For treatment, it must be used in combination with other antiretroviral medications. [7] [8] For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. [7] It does not cure HIV/AIDS. [5] Emtricitabine/tenofovir is taken by mouth. [7]
In 2005, the ACTG opened its first multinational AIDS clinical trial in 16 sites around the globe “A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily PI & Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor - Containing Therapy Combinations for Initial Treatment of HIV-1 Infected individuals from ...
It contains bictegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor; emtricitabine, an HIV-1 nucleoside analog reverse transcriptase inhibitor; and tenofovir alafenamide, an HIV-1 nucleoside analog reverse transcriptase inhibitor. [6]